NCT06546527View on ClinicalTrials.gov

Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

December 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

[177Lu]Lu-PSMA-137

\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06546527 - Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | Biotech Hunter | Biotech Hunter